Biochemical follow‐up of nonfunctioning benign thyroid nodules

Objective For the biochemical follow‐up of benign thyroid nodules, some authors recommend periodic lifelong measurement of thyroid‐stimulating hormone (TSH) to assess for the development of toxic nodules over time. The purpose of this retrospective study was to assess the incidence of thyroid dysfun...

Full description

Saved in:
Bibliographic Details
Published in:Clinical endocrinology (Oxford) 2021-02, Vol.94 (2), p.322-329
Main Authors: Memon, Raafia, Salgado Nunez del Prado, Silvia R., Lamos, Elizabeth M., Mohtasebi, Yasaman, Yip, Terry Cheuk‐Fung, Magder, Laurence, Munir, Kashif M.
Format: Article
Language:English
Subjects:
Diagnosis
Hyperthyroidism
Medical records
Nodules
Patients
subclinical hyperthyroidism
subclinical hypothyroidism
Thyroid
Thyroid diseases
thyroid dysfunction
Thyroid gland
thyroid nodule
Thyroid-stimulating hormone
Ultrasound
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective For the biochemical follow‐up of benign thyroid nodules, some authors recommend periodic lifelong measurement of thyroid‐stimulating hormone (TSH) to assess for the development of toxic nodules over time. The purpose of this retrospective study was to assess the incidence of thyroid dysfunction over time in patients with benign thyroid nodule(s), with a normal TSH at diagnosis and to identify any factors that may predict biochemical dysfunction over time. Methods Medical records of patients with the diagnosis of thyroid nodule(s) between January 2011 and August 2014 were reviewed. Patients who had TSH measurement within 1 year of initial diagnostic ultrasound (US) were included. Results One‐hundred fifty‐seven patients identified with thyroid nodule(s) satisfied inclusion criteria. At a median follow‐up of 45 (34‐63) months, 13 (8.3%) patients developed thyroid dysfunction. The mean initial TSH in the group which developed subclinical hyperthyroidism (0.65 mIU/mL) was statistically different from the group that did not develop thyroid dysfunction (1.37 mIU/mL, P: 0.007). More patients with TSH
ISSN:0300-0664
1365-2265
DOI:10.1111/cen.14303